Brief: Prometheus Biosciences Reports Q1 2022 Results
12/05/2022 21:04
May 12 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES REPORTS FIRST QUARTER 2022
FINANCIAL
RESULTS AND HIGHLIGHTS RECENT CORPORATE PROGRESS
* PROMETHEUS BIOSCIENCES- AS OF MAR 31, 2022, PROMETHEUS
BIOSCIENCES HAD CASH AND CASH EQUIVALENTS OF $227.0 MILLION,
COMPARED TO $257.3 MILLION AT END OF Q4 2021
* QTRLY NET LOSS PER SHARE, BASIC AND DILUTED $0.82
Source text for Eikon: ID:nGNX3B0RF1
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results